A B S T R A C T An inhibitor of transepithelial sodium transport was found in a low molecular weight fraction obtained from serum of patients with far advanced chronic renal disease. In 18 nondialyzed patients, the mean inhibition of short circuit current (SCC) was 24.9 ±2.2% (SE). With a comparable fraction from 11 normal subjects, SCC decreased by only 5.3 ±1.5%. There was significantly greater inhibition with the serum fractions of patients with end stage renal disease being maintained on chronic hemodialysis than in the normal control group; but the degree of inhibition in the dialyzed population was significantly less than that observed in the nondialyzed chronically uremic patients. The inhibition of SCC produced by the serum fractions of a group of seven patients with acute renal failure was not significantly different from the control group despite the presence of high grade uremia in the former. The inhibitory fraction has characteristics identical with the uremic serum fraction which previously has been shown to inhibit p-aminohippurate (PAH) uptake by rabbit kidney cortical slices. With gel filtration through Sephadex G-25, the active fraction appears after the major peaks of substances as small as urea and sodium; hence it may have been retarded on the column. But its ultrafiltration characteristics suggest that its molecular weight may be less than 1000. The inhibitory capability was not destroyed by boiling, freezing, or digestion with chymotrypsin or pronase. Neither methylguanidine nor guanidinosuccinic acid in concentrations well above those present in the serum of uremic patients inhibited sodium transport in the frog skin. The data suggest that there
INTRODUCTION
The maintenance of sodium balance in patients with chronic renal disease is accomplished by means of a progressive increase in the absolute rate of sodium excretion per nephron as the nephron population and the glomerular filtration rate (GFR) diminish. This natriuresis per nephron may be effected in part by an increase in GFR per nephron; but the major factor is a progressive fall in the fraction of filtered sodium reabsorbed (1, 2) . Thus, natriuretic forces capable of diminishing fractional sodium reabsorption must mount in intensity throughout the natural history of chronic renal disease. But the natriuresis per nephron seen with nephron reduction can occur appropriately without a decrease in mineralocorticoid hormone activity (3) . Nor does the natriuresis which occurs in dogs subjected to experimental reduction of their nephron population appear to correlate with changes in cardiac output, mean arterial blood pressure, peripheral resistance, or filtration fractions.' Thus, if there is a natriuretic hormone which contributes normally to the regulation of sodium excretion (4) , its activity might be very high in the blood of patients with advanced chronic renal disease. We recently have described a low molecular weight fraction of uremic serum which inhibits the uptake of p-aminohippurate (PAH) by rabbit kidney cortical slices in vitro (5 For performance of the assay, 500 Al of the concentrated fraction were mixed with an equal volume of anuran Ringer's solution. The ionic composition of the mixture then was adjusted so that the sodium and potassium concentrations, pH, and osmolality were the same as that of the unmodified Ringer.'s solution. The ammonium concentration also was measured routinely and only those samples which contained less than 4 mmoles/liter of ammonium (equivalent to less than 0.4 mmoles/liter in the test system) were used. inhibit sodium transport by the frog skinl (7, 8) . The calcium concentration of the fractions was never high enough to lead to an increase in the final concentration of calcium in the test system. The assay was performed by removing 800 Al of the 4 ml volume of Ringer's solution bathing the inside surface of the skin (serosal surface of the toad bladder) and replacing this by an equal volume of the 1: 1 dilution of the fraction.' Thus the fraction, which had been concentrated tenfold after lyophilization was diluted 1: 10 for assay. The concentration of an inhibitor, therefore, could not have exceeded the in vivo concentration and only if there were no loss of inhibitor in the preparative procedures could it have equalled the in vivo concentration.
After adding the fraction, the short circuit current and potential difference were measured for a 30 min period and the values at the end of this interval were compared with the steady-state control values. The data are expressed as percentage changes from the control. In all but two assays, two separate samples of each fraction were tested using frog skin preparations or toad bladders from different animals; the results of the two tests were averaged.
Several additional groups of experiments were performed. In one set the inhibitory capacity of the fraction from normal and uremic subjects was measured before and after ultrafiltration through a Diaflo UM 2 membrane.7 The UM 2 membrane is designed to retain substances with an average molecular weight greater than about 1000. Ultrafiltration was performed with nitrogen gas at a pressure of 20 lbs. per square inch (p.s.i.). Fractions also were tested before and after boiling for 10 min and before and after incubation with pronase and chymotrypsin.8 For the latter studies, the concentrated fraction was incubated with pronase or chymotrypsin (1 mg/ml) for 30-60 min at 370C at pH 7.4. At the end of the incubation the mixture was boiled for 10 min in a test tube covered with a glass tear to prevent loss by evaporation. Control observations for these studies were obtained by using the same fractions processed in the same 'The serum fractions were systematically added to the inside or serosal surface of the membranes, since in pilot experiments, the fraction from uremic patients decreased short circuit current in the toad bladder by an average of 35% (-30 to -44%) when added to the serosal solution, but when added to the mucosal solution, the current changed by a mean of +2.5% (-8 Finally a series of experiments was performed in which whole serum from uremic patients and normal subjects was ultrafiltered through Diaflo XM 50 or UM 10 membranes. These membranes have an average molecular weight rejection of 50,000 and 10,000, respectively. The ultrafiltrates were diluted so that their sodium concentration would equal that of the anuran Ringer's solution. At the end of the equilibration period, the Ringer's solutions bathing both surfaces of the frog skin were removed by gravity and replaced by 4-ml quantities of ultrafiltrate.
Sodium and potassium were determined by flame photometry, calcium by atomic absorption spectrophotometry, BUN by the method of Marsh, Fingerhut, and Miller (9) adapted to the Technicon AutoAnalyzer, osmolality with a Fiske osmometer, and pH with a glass electrode. Ammonium was measured by the microdiffusion method of Conway (10) . PAH uptake by rabbit kidney cortical slices was measured as previously reported (5). The variation for sets of measurements is expressed as the standard error of the mean. Statistical analysis was performed using Student's t test, and significance in the text is expressed as the 2P value.' RESULTS A representative experiment depicting the effects of a fraction from a chronically uremic nondialyzed patient is shown in Fig. 2 . Following addition of the fraction to the Ringer's solution bathing the inside surface of the frog skin, both the short circuit current and the potential difference decreased. The inhibition typically was delayed for 5-10 min and progressed during the ensuing 20-30 min. When the Ringer's solution containing the fraction was removed and replaced with fresh Ringer, values for both short circuit current and potential difference increased toward the control level. Fig. 3 fects of the comparable serum fraction from a normal average value for GFR in the uremic patients was 5.5 subject. There was no change in either short circuit or ml/minute (range 2.0-15) and the mean BUN was 140 potential difference. With the exception of the first two mg/100 ml (range 58-267). The mean inhibition of short fractions, which could not be tested in the present assay circuit current with the normal serum fractions was 5.3 system, none of the other fractions of serum inhibited ±+1.5%. In contrast, the samples from the 18 chronically short circuit.
uremic patients produced a mean decrease in short cir- Table I presents the data from the 11 normal subjects cuit current of 24.9 ±2.2%. This value differs signifiand 18 nondialyzed patients with chronic uremia. The cantly from the value obtained for the group of normal Ringer's solution on both sides of the skin. subjects (P < 0.001). Following removal of the fraction from the chronically uremic patients and the addition of fresh Ringer's solution, short circuit current recovered towards the control value in a highly consistent fashion. When the normal fraction was replaced, small changes in short circuit current were observed. The difference in recovery of the short circuit current between the normal and the uremic groups was highly significant (P < 0.001). Table II presents the results of 11 studies in which the inhibitory capacity of the uremic fraction was measured before and after ultrafiltration through a Diaflo UM 2 membrane. Each of 11 fractions inhibited short circuit either circumstance. Of interest is the fact that when whole uremic serum, rather than the gel filtration fraction, was ultrafiltered, no inhibition was obtained with the ultrafiltrates from membranes having molecular weight exclusions of 10,000 and 50,000 (see Table II ). Certain additional characteristics of the inhibitory factor are presented in Fig. 4 . Inhibition of sodium transport persisted after boiling the fraction for 10 min. It also persisted after digestion with pronase and subsequent boiling and after digestion with chymotrypsin and subsequent boiling. The inhibitory activity was not affected by freezing of the fraction for periods of up to 4 wk; it also could be obtained from sera which were stored at -80'C for periods as long as 10 wk before fractionation through Sephadex.
Recent interest has been devoted to two compounds which are retained in the serum of uremic patients and which are believed to represent uremic toxins. One is methylguanidine (11) , the other guanidinosuccinic acid (12) . To examine the possible relevance of each of these compounds to the present observations, their effects on the short circuit current of the isolated frog skin were measured, using a protocol identical with that employed for the assay of the serum fractions. The results are presented in Table III . After obtaining control observations, methylguanidine was added to the Ringer's solution bathing the inside surface of the skin in a final concentration of 1 mmole/liter. The mean change in short circuit current for six experiments was -4% and the maximum decrease observed was 9%. Guanidinosuccinic acid also was added to the inside solution in a final concentration of 1 mmole/liter. The mean change in short circuit current for five experiments was -2.6%. Values increased in three, decreased in one, and remained unchanged in one experiment.
The results of studies performed with the serum fractions from seven patients with acute renal failure are shown in Table IV . Five of the patients had acute tubular necrosis, one bilateral cortical necrosis, and one bilateral renal infarction. Five of the patients were anuric or oliguric and two had nonoliguric renal failure. Three of the patients had been dialyzed, four had not. At the time the blood for assay was obtained, the average value for the BUN was 127 mg/100 ml (range 92-165), a value not significantly different from that from the 18 patients with chronic renal disease shown in Table I . Of interest is the fact that, in contrast to the data presented in Table I , the serum fractions from only two of the seven patients produced substantial inhibition of short circuit current. Both of these patients were nonoliguric at the time of blood sampling. Neither had been dialyzed. Of the remaining five patients, three had been dialyzed, two had not.
16 samples were obtained from 13 patients with chronic urcnia who were being maintained on chronic hemodialysis. Blood was obtained just before beginning dialysis and thus, usually, 72 hr after the previous dialysis. The average BUN was 79 mg/100 ml (range 35-104). Inhibition of short circuit current averaged 16.1 ±2.1%.
3 of the 13 patients were anephric. The serum fraction from two of the anephric patients inhibited the short circuit current by 16 and 23%, respectively. The sample from the third anephric patient decreased the short circuit current by 6%.
The composite data for the normal subjects, the patients with acute renal failure and the two groups of patients with chronic renal failure are shown in Fig. 5 . The mean inhibtion produced by the fractions from seven patients with acute renal failure was 6.8 ±3.0%, a value not significantly different from the value of 5.3 +1.5% observed for normal subjects. The inhibition produced by the fractions from the 13 uremic patients on chronic hemodialysis (16.1 +2.1%) is significantly different from that for the normal subjects (P < 0.01) and for the subjects with acute renal failure (P <0.05). It is also significantly lower than the value of 24.9 +2.2% for the nondialyzed chronic uremic patients (P < 0.005).
As has been noted above, the same fraction from uremic serum which inhibits sodium transport by the frog skin and toad bladder has previously been found to inhibit PAH uptake by rabbit kidney cortical slices. Moreover the PAH inhibitor also is resistant to boiling, freezing, and digestion with pronase and chymotrypsin. In Table III , nine experiments are shown in which the same fractions and ultrafiltrates were tested both on sodium transport by the anuran membrane and on PAH uptake by rabbit kidney cortical slices. Three of the assays were performed using material from normal subjects, three from nondialyzed chronic uremic patients, and three from dialyzed chronic uremic patients. For the entire group, the correspondence between the two assay systems is good. 
DISCUSSION
The present data demonstrate the existence of a substance (or perhaps substances) in the serum of patients with chronic uremia which inhibits transepithelial sodium transport by the isolated frog skin. The active material was extracted from uremic serum via molecular sieving using Sephadex G-25, and it appeared in a low molecular weight fraction. When this fraction was added to the Ringer's solution bathing the inside surface (i.e. blood side) of the isolated frog skin in a concentration which could not have exceeded the in vivo level in the donor uremic patients, short circuit current fell predictably. After a lag period of approximately 5-10 min, short circuit current began to decrease and the decrement persisted for 25-30 min. When the Ringer's solution containing the inhibitory fraction was removed and replaced with fresh anuran Ringer, short circuit current returned towards the control level. The potential difference across the skin fell and subsequently rose in a manner which was qualitatively similar to the changes in the short circuit current.
Certain of the characteristics of the inhibitory material are apparent in the present studies. The serum fraction containing the inhibitor was eluted from Sephadex G-25 after the major peaks of sodium, potassium, creatinine, and urea. It seems very unlikely, however, that the molecular weight of the inhibitor could be less than that of the sodium ion; hence, the inhibitory compound probably was retarded on the Sephadex column. The studies performed with Diaflo UM 2 membranes suggest that the molecular weight is low, possibly less than 1000; at least the inhibitor passed freely through a filter designed to prevent the filtration of molecules with an average molecular weight greater than approxi- Nondialyzed chronic uremic patients 4.
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Results are expressed as the per cent change of control short circuit current (see Methods) and of control PAH uptake (uptake of PAH by kidney slices incubated in Ringer's solution to which the serum fraction was not added).
The isolated toad bladder was used for samples 1-4, and the frog skin for the remaining samples.
mately 1000.n The inhibitor resisted boiling and freezing.
It also resisted digestion by two agents, pronase and chymotrypsin, which destroy certain peptide compounds. Nevertheless, the failure of these two enzymes to inactivate the inhibitor does not exclude the possibility that it might be a low molecular weight peptide. The studies simply do not provide any support for this possibility.
The inhibitor of sodium transport by the frog skin appears to have certain of the same characteristics as the substance obtained from uremic serum that inhibits PAH uptake by jrabbit kidney cortical slices (13) . Both inhibitors were obtained from the serum of patients with chronic uremia; both appeared in the same low molecular weight fraction following filtration through Sephadex G-25; and both had the same elution characteristics. Both inhibitors resisted boiling, freezing, and digestion with chymotrypsin and pronase. Moreover, when the same serum fractions or ultrafiltrates were tested in the two assay systems, the effects observed were comparable. Thus the inhibitor obtained from uremic serum may be active in at least two different systems involving the transport of two different solute species.
12 Buckalew, Martinez, and Green (19) recently have cited as a personal communication the fact that compounds with molecular weights as high as 3000 and with the appropriate configuration may pass through the UM 2 membrane.
The relationship of our material to the humoral inhibitor(s) of sodium transport described by other groups of investigators in the blood of nonuremic animals and man (14) (15) (16) (17) (18) (19) (20) remains to be determined. Cort and associates have described observations which they believe demonstrate the presence of an inhibitor of sodium transport in the serum following carotid artery occlusion in cats (14, 15) and acute volume expansion with isosmotic isoncotic dextran infusions in cows (16) Table II involving ultrafiltration of whole uremic serum. When whole serum rather than the gel filtration fraction was subjected to ultrafiltration using Diaflo XM 50 and UM 10 membranes, with an average molecular weight rejection of 50,000 and 10,000, respectively, the ultrafiltrates failed to inhibit transepithelial sodium transport by the frog skin. Thus if the inhibitor is protein bound, it would appear to be separated in the process of gel filtration through Sephadex G-25 but would remain bound when subjected to ultrafiltration at a pressure of 20 p.s.i.
Recently, Buckalew, Martinez, and Green have described a circulating inhibitor of sodium transport by the isolated toad bladder in dogs with extracellular fluid volume expansion imposed either by acute saline loading (19) or long-term administration of mineralocorticoid hormones (20) . The substance was obtained from plasma following ultrafiltration through Diaflo UM 10 and UM 2 membranes which, as indicated above have a molecular weight cut-off of approximataely 10,000 and 1000, respectively. The inhibitor also was obtained in the dialysate following dialysis with a Klung dialyzer. On the basis of the Diaflo experiments, the molecular weight of this inhibitor would appear to correspond closely to that of the inhibitor obtained in the present studies from uremic serum and so also would its capacity to inhibit transepithelial sodium transport by an anuran membrane. However, there is a difference which would appear to be of a substantive nature. In the former studies the inhibitor could be obtained in the ultrafiltrate with UM 10 and UM 2 Diaflo membranes; whereas in the present studies, when whole serum was used the inhibition was not observed with the filtrate of UM 10 or XM 50 membranes. Thus none of the inhibitors of sodium transport found in nonuremic animals or man corresponds precisely to the inhibitor described in the present studies and the exact relationship between the uremic inhibitor and the circulating substances described in volume expansion requires further exploration.
It is of interest that inhibition was produced by the serum fractions from only two of seven patients with acute renal failure despite the fact that all seven had high-grade uremia. Thus, whatever the nature of the substance, it apparently takes time to appear in detectable activity in the serum. It is also of interest that the only two patients who manifested inhibition in their serum fraction were nonoliguric at the time blood was obtained. Additional studies are obviously necessary to examine the consistency of this relationship. Inhibition was obtained in chronic uremic patients who were maintained on chronic dialysis, but the mean inhibition for group data was significantly less than that for the nondialyzed chronic patients. To date, studies have not been performed in which blood obtained before and immediately after hemodialysis was compared. The fact that the inhibitor was present in two of three anephric patients would indicate that it is not synthesized by the kidneys.
It is not yet clear whether the substance described in these studies is a hormone or a metabolic product retained in uremia. However, if it is a hormone, it seems likely that the hormonal activity increases as part of the adaptation in the sodium control system which leads to a progressive increase in sodium excretion rate per nephron as the nephron population diminishes. Moreover, if the inhibitor, whatever its nature, is present in sufficiently high concentration in uremia to affect solute transport in extrarenal systems, it could ultimately contribute importantly to certain of the symptoms and signs of the uremic state.
